Vertex Pharmaceuticals reported total revenues of $3.44 billion for the third quarter of 2026, a 12% increase compared to the same period in 2025. Net income for the quarter was $653.6 million, down from $1.08 billion in the prior year, primarily driven by significantly higher operating expenses and a $9.06 billion acquisition of Crinetics Pharmaceuticals.
Vertex Pharmaceuticals reported Q3 2026 revenue of $3.44 billion, a 12% increase year-over-year, driven by strong demand for its cystic fibrosis therapies and new product launches. The company raised its full-year 2026 revenue guidance to a range of $13.15 billion to $13.25 billion. During the quarter, Vertex also completed the $9 billion acquisition of Crinetics Pharmaceuticals and secured a $4.5 billion term loan.
“Vertex delivered excellent third quarter results marked by strong revenue growth across the increasingly diversified portfolio, continued advancement of the R&D pipeline, and the successful close of the Crinetics Pharmaceuticals acquisition.”
Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex
“With the potential povetacicept approval in IgAN coming later this month, we are well positioned to establish nephrology as our fifth commercial franchise and expand the reach of our transformative medicines to even more patients.”
Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex